Similar articles

• Approaches to interrupting HAART for the treatment of HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.

  Dybul M; National Institute of Allergy and Infectious Disease, US National Institutes of Health, USA. Dybul M, et al. IAPAC Mon. 2001 Aug;7(8):232-4. IAPAC Mon. 2001. PMID: 11708275 No abstract available.
• Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

  Valer L, González de Requena D, de Mendoza C, Martin-Carbonero L, González-Lahoz J, Soriano V. Valer L, et al. AIDS Patient Care STDS. 2004 Jan;18(1):1-6. doi: 10.1089/108729104322740857. AIDS Patient Care STDS. 2004. PMID: 15006188 Clinical Trial.
• How individual can personalized antiretroviral treatment be? Deep salvage in an HIV-1-infected patient.

  Jensen B, Esser S, Kaiser R, Luebke N, Häussinger D. Jensen B, et al. Intervirology. 2012;55(2):167-71. doi: 10.1159/000332020. Epub 2012 Jan 24. Intervirology. 2012. PMID: 22286888
• Structured treatment interruption in HIV infection.

  Benson CA. Benson CA. AIDS Read. 2001 Feb;11(2):99-102. AIDS Read. 2001. PMID: 11279889 Review.
• HIV therapeutics: points from the recent literature.

  Laurence J. Laurence J. AIDS Read. 2003 Jul;13(7):305, 307. AIDS Read. 2003. PMID: 12889448 Review. No abstract available.